Basavarajappa Balapal S
Division of Analytical Psychopharmacology, New York State Psychiatric Institute, New York, NY 10032, USA.
Curr Neuropharmacol. 2007;5(2):81-97. doi: 10.2174/157015907780866910.
The endocannabinoid signaling system is composed of the cannabinoid receptors; their endogenous ligands, the endocannabinoids; the enzymes that produce and inactivate the endocannabinoids; and the endocannabinoid transporters. The endocannabinoids are a new family of lipidic signal mediators, which includes amides, esters, and ethers of long-chain polyunsaturated fatty acids. Endocannabinoids signal through the same cell surface receptors that are targeted by Delta(9)-tetrahydrocannabinol (Delta(9)THC), the active principles of cannabis sativa preparations like hashish and marijuana. The biosynthetic pathways for the synthesis and release of endocannabinoids are still rather uncertain. Unlike neurotransmitter molecules that are typically held in vesicles before synaptic release, endocannabinoids are synthesized on demand within the plasma membrane. Once released, they travel in a retrograde direction and transiently suppress presynaptic neurotransmitter release through activation of cannabinoid receptors. The endocannabinoid signaling system is being found to be involved in an increasing number of pathological conditions. In the brain, endocannabinoid signaling is mostly inhibitory and suggests a role for cannabinoids as therapeutic agents in central nervous system (CNS) disease. Their ability to modulate synaptic efficacy has a wide range of functional consequences and provides unique therapeutic possibilities. The present review is focused on new information regarding the endocannabinoid signaling system in the brain. First, the structure, anatomical distribution, and signal transduction mechanisms of cannabinoid receptors are described. Second, the synthetic pathways of endocannabinoids are discussed, along with the putative mechanisms of their release, uptake, and degradation. Finally, the role of the endocannabinoid signaling system in the CNS and its potential as a therapeutic target in various CNS disease conditions, including alcoholism, are discussed.
内源性大麻素信号系统由大麻素受体、其内源性配体(即内源性大麻素)、产生和灭活内源性大麻素的酶以及内源性大麻素转运体组成。内源性大麻素是一类新的脂质信号介质家族,包括长链多不饱和脂肪酸的酰胺、酯和醚。内源性大麻素通过与大麻(如哈希什和大麻)制剂中的活性成分Δ⁹-四氢大麻酚(Δ⁹THC)靶向的相同细胞表面受体进行信号传导。内源性大麻素合成和释放的生物合成途径仍相当不确定。与通常在突触释放前储存在囊泡中的神经递质分子不同,内源性大麻素是在质膜内按需合成的。一旦释放,它们会逆向移动,并通过激活大麻素受体短暂抑制突触前神经递质的释放。人们发现内源性大麻素信号系统参与越来越多的病理状况。在大脑中,内源性大麻素信号传导大多具有抑制作用,这表明大麻素在中枢神经系统(CNS)疾病中作为治疗剂具有一定作用。它们调节突触效能的能力具有广泛的功能后果,并提供了独特的治疗可能性。本综述聚焦于大脑中内源性大麻素信号系统的新信息。首先,描述了大麻素受体的结构、解剖分布和信号转导机制。其次,讨论了内源性大麻素的合成途径,以及它们释放、摄取和降解的推定机制。最后,讨论了内源性大麻素信号系统在中枢神经系统中的作用及其作为包括酒精中毒在内的各种中枢神经系统疾病状况治疗靶点的潜力。